Multiple Myeloma: all 3,712 studies

Page 11 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.

• Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 RearrangementCompletedNCT02765854Phase 2Results posted
• An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma ParticipantsTerminatedNCT02761187Results posted
• ABC294640 (Opaganib) in Refractory / Relapsed Multiple MyelomaTerminatedNCT02757326Phase 1/2Results posted
• A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT02755597Phase 3Results posted
• A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple MyelomaTerminatedNCT02749617Phase 2Results posted
• Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple MyelomaTerminatedNCT02739594Phase 3Results posted
• Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)CompletedNCT02728102Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple MyelomaCompletedNCT02726581Phase 3Results posted
• Panobinostat (LBH589): Multiple Myeloma - Autologous Hematopoietic Cell Transplantation (HCT)CompletedNCT02722941Phase 2Results posted
• UCB Transplant for Hematological Diseases Using a Non Myeloablative PrepCompletedNCT02722668Phase 2Results posted
• A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)TerminatedNCT02720510Phase 2Results posted
• Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell TransplantTerminatedNCT02716805Phase 1Results posted
• Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesTerminatedNCT02711137Phase 1/2Results posted
• Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)CompletedNCT02703779Phase 2Results posted
• Enhancing Anti--Tetanus Vaccine Response After Autologous Stem Cell TransplantationTerminatedNCT02700841Phase 2Results posted
• A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple MyelomaCompletedNCT02685826Phase 1/2Results posted
• Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceTerminatedNCT02681302Phase 1/2Results posted
• AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid LeukemiaTerminatedNCT02675452Phase 1Results posted
• Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous TransplantationCompletedNCT02669615Phase 2Results posted
• SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple MyelomaTerminatedNCT02661022Phase 1/2Results posted
• Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple MyelomaCompletedNCT02654990Phase 2Results posted
• An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)CompletedNCT02654132Phase 2Results posted
• Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological MalignanciesCompletedNCT02639559Phase 2Results posted
• Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT02633059Phase 1/2Results posted
• Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning Chemotherapy for Autologous SCTTerminatedNCT02619812Phase 2Results posted
• Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02619682Phase 2Results posted
• A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.CompletedNCT02612779Phase 2Results posted
• High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple MyelomaCompletedNCT02597062Phase 2Results posted
• Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD ProphylaxisCompletedNCT02593123Phase 2Results posted
• Reduced Intensity Conditioning Transplant Using Haploidentical DonorsCompletedNCT02581007Phase 2Results posted
• Study of Lenalidomide and Dexamethasone With or Without Pembrolizumab (MK-3475) in Participants With Newly Diagnosed Treatment Naive Multiple Myeloma (MK-3475-185/KEYNOTE-185)TerminatedNCT02579863Phase 3Results posted
• Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)TerminatedNCT02576977Phase 3Results posted
• Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT02566304Phase 2Results posted
• Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy PatientsCompletedNCT02566265Phase 2Results posted
• A Phase 1 Study in Subjects With Relapsed or Refractory Multiple MyelomaCompletedNCT02561962Phase 1Results posted
• Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft MalignanciesCompletedNCT02556931Phase 2Results posted
• Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple MyelomaTerminatedNCT02548962Phase 1/2Results posted
• Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell LeukemiaCompletedNCT02547662Phase 2Results posted
• A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple MyelomaCompletedNCT02541383Phase 3Results posted
• BiRd vs. Rd as Initial Therapy in Multiple MyelomaTerminatedNCT02516696Phase 3Results posted
• Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma PatientsCompletedNCT02514239Phase 1Results posted
• Leflunomide in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02509052Phase 1/2Results posted
• Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedNCT02506959Phase 2Results posted
• UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib TreatmentCompletedNCT02499081Phase 2Results posted
• Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple MyelomaCompletedNCT02492750Phase 1Results posted
• Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple MyelomaCompletedNCT02481934Phase 1Results posted
• Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple MyelomaCompletedNCT02477215Phase 1/2Results posted
• Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple MyelomaCompletedNCT02441686Phase 2Results posted
• Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)CompletedNCT02440464Phase 2Results posted
• Optimising Renal Outcome in Myeloma Renal FailureCompletedNCT02424851Phase 2Results posted
• Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT RecipientsCompletedNCT02420223Phase 2Results posted
• High Dose Chemotherapy Using BeEAM for Autologous Transplant in Multiple MyelomaCompletedNCT02416206Phase 2Results posted
• Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple MyelomaCompletedNCT02412878Phase 3Results posted
• Ixazomib, Cyclophosphamide and Dexamethasone for Multiple MyelomaCompletedNCT02412228Phase 2Results posted
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)TerminatedNCT02393248Phase 1/2Results posted
• Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell TransplantCompletedNCT02389517Phase 2Results posted
• Vertebral Augmentation and Radiotherapy of Collapse Spinal Metastatic CancerTerminatedNCT02376933Not applicableResults posted
• Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MMCompletedNCT02375555Phase 2Results posted
• ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
• Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationCompletedNCT02356159Phase 1/2Results posted
• Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple MyelomaTerminatedNCT02353572Phase 1/2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell TransplantTerminatedNCT02353468Phase 2Results posted
• Selinexor Treatment of Refractory MyelomaCompletedNCT02336815Phase 2Results posted
• Phase 1b Study of Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02335983Phase 1Results posted
• Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple MyelomaCompletedNCT02331368Phase 2Results posted
• Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell MalignanciesCompletedNCT02328014Phase 1/2Results posted
• Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)CompletedNCT02322320Phase 3Results posted
• A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple MyelomaCompletedNCT02316106Phase 2Results posted
• A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)CompletedNCT02312258Phase 3Results posted
• Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT02290431Phase 2Results posted
• 1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT02289222Phase 1/2Results posted
• E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple MyelomaCompletedNCT02279394Phase 2Results posted
• Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in JapanCompletedNCT02272803Phase 2Results posted
• Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple MyelomaTerminatedNCT02254551Phase 2Results posted
• Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple MyelomaActive, not recruitingNCT02253316Phase 2Results posted
• Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple MyelomaCompletedNCT02252172Phase 3Results posted
• Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT02224729Phase 2Results posted
• Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple MyelomaCompletedNCT02215967Phase 1Results posted
• An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple MyelomaCompletedNCT02211014Phase 1Results posted
• A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple MyelomaCompletedNCT02195479Phase 3Results posted
• UARK 2014-21 A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles VirusCompletedNCT02192775Phase 2Results posted
• Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple MyelomaCompletedNCT02186834Phase 1/2Results posted
• A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell TransplantCompletedNCT02181413Phase 3Results posted
• Nonmyeloablative Haploidentical Transplant Followed by MLN9708CompletedNCT02169791Phase 2Results posted
• Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple MyelomaCompletedNCT02168101Phase 2Results posted
• Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma PatientsCompletedNCT02159365Phase 2Results posted
• Combined Bone Marrow and Renal Transplantation for Hematologic Disorders With End Stage Renal DiseaseCompletedNCT02158052Not applicableResults posted
• Phase I: Melphalan, Bendamustine and Carfilzomib for Autologous Transplant in Multiple MyelomaCompletedNCT02148913Phase 1Results posted
• Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02136134Phase 3Results posted
• UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete RemissionTerminatedNCT02128230Phase 2Results posted
• Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple MyelomaCompletedNCT02119468Phase 1/2Results posted
• A Study of Granix to Disrupt the Bone Marrow Microenvironment in Patients With Multiple Myeloma Undergoing Autologous TransplantationTerminatedNCT02112045Phase 2Results posted
• PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease PatientsCompletedNCT02104427Phase 2Results posted
• Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple MyelomaCompletedNCT02100657Phase 1Results posted
• QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT02099539Phase 1Results posted
• Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin LymphomaCompletedNCT02098109Phase 2Results posted
• Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple MyelomaCompletedNCT02086552Phase 2Results posted
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK2816126 in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma, Transformed Follicular Lymphoma, Other Non-Hodgkin's Lymphomas, Solid Tumors and Multiple MyelomaTerminatedNCT02082977Phase 1Results posted
• A Study of Avastin (Bevacizumab) in Patients With Multiple MyelomaTerminatedNCT02079519Phase 2Results posted
• A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's LymphomaCompletedNCT02078102Phase 2Results posted

← Multiple Myeloma overview